메뉴 건너뛰기




Volumn 25, Issue 6, 2016, Pages 1321-1330

Direct oral anticoagulants in patients with thrombophilia: Challenges in diagnostic evaluation and treatment

Author keywords

Anticoagulant drugs; Antiphospholipid syndrome; Thrombophilia

Indexed keywords

ACTIVATED PROTEIN C; ANTICOAGULANT AGENT; ANTITHROMBIN; ANTIVITAMIN K; APIXABAN; BLOOD CLOTTING FACTOR 5 LEIDEN; DABIGATRAN; LUPUS ANTICOAGULANT; PROTEIN C; PROTEIN S; PROTHROMBIN; RIVAROXABAN;

EID: 85006747536     PISSN: 18995276     EISSN: 24512680     Source Type: Journal    
DOI: 10.17219/acem/65853     Document Type: Review
Times cited : (14)

References (78)
  • 1
    • 84908349388 scopus 로고    scopus 로고
    • Efficacy and safety of the new oral anticoagulants dabigatran, rivaroxaban, apixaban, and edoxaban in the treatment and secondary prevention of venous thromboembolism: A systematic review and meta-analysis of phase III trials
    • Kakkos SK, Kirkilesis GI, Tsolakis IA: Efficacy and safety of the new oral anticoagulants dabigatran, rivaroxaban, apixaban, and edoxaban in the treatment and secondary prevention of venous thromboembolism: A systematic review and meta-analysis of phase III trials. Eur J Vasc Endovasc Surg 2014, 48, 565-575.
    • (2014) Eur J Vasc Endovasc Surg , vol.48 , pp. 565-575
    • Kakkos, S.K.1    Kirkilesis, G.I.2    Tsolakis, I.A.3
  • 2
    • 84908476214 scopus 로고    scopus 로고
    • Prevention of ischemic stroke in clinical practice: A role of internists and general practitioners
    • Niewada M, Członkowska A: Prevention of ischemic stroke in clinical practice: A role of internists and general practitioners. Pol Arch Med Wewn 2014, 124, 540-548.
    • (2014) Pol Arch Med Wewn , vol.124 , pp. 540-548
    • Niewada, M.1    Członkowska, A.2
  • 3
    • 84908550562 scopus 로고    scopus 로고
    • Failure of dabigatran and rivaroxaban to prevent thromboembolism in antiphospholipid syndrome: A case series of three patients
    • Schaefer JK, McBane RD, Black DF: Failure of dabigatran and rivaroxaban to prevent thromboembolism in antiphospholipid syndrome: A case series of three patients. Thromb Haemost 2014, 112, 947-950.
    • (2014) Thromb Haemost , vol.112 , pp. 947-950
    • Schaefer, J.K.1    McBane, R.D.2    Black, D.F.3
  • 4
    • 84907994966 scopus 로고    scopus 로고
    • New oral anticoagulants may not be effective to prevent venous thromboembolism in patients with antiphospholipid syndrome
    • Win K, Rodgers GM: New oral anticoagulants may not be effective to prevent venous thromboembolism in patients with antiphospholipid syndrome. Am J Hematol 2014, 89, 1017.
    • (2014) Am J Hematol , vol.89 , pp. 1017
    • Win, K.1    Rodgers, G.M.2
  • 5
    • 84994226102 scopus 로고    scopus 로고
    • Optimizing the safety of treatment for venous thromboembolism in the era of the direct oral anticoagulants
    • (in press)
    • Weitz JL, Jaffer IH: Optimizing the safety of treatment for venous thromboembolism in the era of the direct oral anticoagulants. Pol Arch Med Wewn 2016 (in press).
    • (2016) Pol Arch Med Wewn
    • Weitz, J.L.1    Jaffer, I.H.2
  • 6
    • 84924324904 scopus 로고    scopus 로고
    • How to predict short- and long-term mortality in patients with pulmonary embolism?
    • Dentali F, Cei M, Mumoli N, Gianni M: How to predict short- and long-term mortality in patients with pulmonary embolism? Pol Arch Med Wewn 2015, 125, 82-88.
    • (2015) Pol Arch Med Wewn , vol.125 , pp. 82-88
    • Dentali, F.1    Cei, M.2    Mumoli, N.3    Gianni, M.4
  • 7
    • 84906849418 scopus 로고    scopus 로고
    • How to predict and diagnose postthrombotic syndrome
    • Rabinovich A, Kahn SR: How to predict and diagnose postthrombotic syndrome. Pol Arch Med Wewn 2014, 124, 410-416.
    • (2014) Pol Arch Med Wewn , vol.124 , pp. 410-416
    • Rabinovich, A.1    Kahn, S.R.2
  • 8
    • 84894185693 scopus 로고    scopus 로고
    • Venous thrombosis: Who should be screened for thrombophilia in 2014?
    • Kyrle PA: Venous thrombosis: Who should be screened for thrombophilia in 2014? Pol Arch Med Wewn 2014, 124, 65-69.
    • (2014) Pol Arch Med Wewn , vol.124 , pp. 65-69
    • Kyrle, P.A.1
  • 11
    • 84891701713 scopus 로고    scopus 로고
    • Use of new oral anticoagulants in antiphospholipid syndrome
    • Arachchillage DJ, Cohen H: Use of new oral anticoagulants in antiphospholipid syndrome. Curr Rheumatol Rep 2013, 15, 331.
    • (2013) Curr Rheumatol Rep , vol.15 , pp. 331
    • Arachchillage, D.J.1    Cohen, H.2
  • 12
    • 84907684888 scopus 로고    scopus 로고
    • Practical aspects of new oral anticoagulant use in atrial fibrillation
    • Undas A, Pasierski T, Windyga J, Crowther M: Practical aspects of new oral anticoagulant use in atrial fibrillation. Pol Arch Med Wewn 2014, 124, 124-135.
    • (2014) Pol Arch Med Wewn , vol.124 , pp. 124-135
    • Undas, A.1    Pasierski, T.2    Windyga, J.3    Crowther, M.4
  • 13
    • 55949104988 scopus 로고    scopus 로고
    • Inherited antithrombin deficiency: A review
    • Patnaik MM, Moll S: Inherited antithrombin deficiency: A review. Haemophilia 2008, 14, 1229-1239.
    • (2008) Haemophilia , vol.14 , pp. 1229-1239
    • Patnaik, M.M.1    Moll, S.2
  • 14
    • 84946553053 scopus 로고    scopus 로고
    • Classic thrombophilic gene variants
    • Manucci PM, Franchini M: Classic thrombophilic gene variants. Thromb Haemost 2015, 114, 885-889.
    • (2015) Thromb Haemost , Issue.114 , pp. 885-889
    • Manucci, P.M.1    Franchini, M.2
  • 15
    • 79961046359 scopus 로고    scopus 로고
    • Arterial and venous thrombosis and prothrombotic fibrin clot phenotype in a Polish family with type 1 antithrombin deficiency (antithrombin Krakow)
    • Celinska-Lowenhoff M, Iwaniec T, Alhenc-Gelas M, Musial J, Undas A: Arterial and venous thrombosis and prothrombotic fibrin clot phenotype in a Polish family with type 1 antithrombin deficiency (antithrombin Krakow). Thromb Haemost 2011, 106, 379-381.
    • (2011) Thromb Haemost , vol.106 , pp. 379-381
    • Celinska-Lowenhoff, M.1    Iwaniec, T.2    Alhenc-Gelas, M.3    Musial, J.4    Undas, A.5
  • 19
    • 84879944753 scopus 로고    scopus 로고
    • Antithrombin Rybnik: A new point mutation (nt 683 G > T) associated with type i antithrombin deficiency in a patient with venous thromboembolism and recurrent superficial venous thrombosis
    • Szymańska M, Alhenc-Gelas M, Undas A: Antithrombin Rybnik: A new point mutation (nt 683 G > T) associated with type I antithrombin deficiency in a patient with venous thromboembolism and recurrent superficial venous thrombosis. Blood Coagul Fibrinolysis 2013, 24, 579-580.
    • (2013) Blood Coagul Fibrinolysis , vol.24 , pp. 579-580
    • Szymańska, M.1    Alhenc-Gelas, M.2    Undas, A.3
  • 20
    • 84920856416 scopus 로고    scopus 로고
    • Antithrombin Katowice: Exon 1 deletion in the SERPINC1 gene associated with type I antithrombin deficiency
    • Cieśla M, Wypasek E, Corral J, Alhence-Gelas M, Undas A: Antithrombin Katowice: Exon 1 deletion in the SERPINC1 gene associated with type I antithrombin deficiency. Blood Coagul Fibrinolysis 2015, 26, 95-97.
    • (2015) Blood Coagul Fibrinolysis , vol.26 , pp. 95-97
    • Cieśla, M.1    Wypasek, E.2    Corral, J.3    Alhence-Gelas, M.4    Undas, A.5
  • 23
    • 84975460425 scopus 로고    scopus 로고
    • Heparin-resistant thrombosis due to homozygous antithrombin deficiency treated with rivaroxaban: A case report
    • (in press)
    • Van Bruwaene L, Huisman A, Urbanus RT, Versluys B: Heparin-resistant thrombosis due to homozygous antithrombin deficiency treated with rivaroxaban: A case report. J Pediatr Hematol Oncol 2016 (in press).
    • (2016) J Pediatr Hematol Oncol
    • Van Bruwaene, L.1    Huisman, A.2    Urbanus, R.T.3    Versluys, B.4
  • 24
    • 40349088826 scopus 로고    scopus 로고
    • Thrombophilias: When should we test and how does it help?
    • Whitlatch NL, Ortel TL: Thrombophilias: When should we test and how does it help? Semin Respir Crit Care Med 2008, 29, 25-39.
    • (2008) Semin Respir Crit Care Med , vol.29 , pp. 25-39
    • Whitlatch, N.L.1    Ortel, T.L.2
  • 25
    • 84883263094 scopus 로고    scopus 로고
    • A missense mutation G109R in the PROC gene associated with type i protein C deficiency in a young Polish man with acute myocardial infarction
    • Wypasek E, Pankiw-Bembenek O, Potaczek DP, Alhenc-Gelas M, Trebacz J, Undas A: A missense mutation G109R in the PROC gene associated with type I protein C deficiency in a young Polish man with acute myocardial infarction. Int J Cardiol 2013,167, 146-148.
    • (2013) Int J Cardiol , vol.167 , pp. 146-148
    • Wypasek, E.1    Pankiw-Bembenek, O.2    Potaczek, D.P.3    Alhenc-Gelas, M.4    Trebacz, J.5    Undas, A.6
  • 26
    • 84894183623 scopus 로고    scopus 로고
    • Novel missense mutation C106R in the PROC gene associated with type i protein C deficiency in a young Polish man with high-risk pulmonary embolism
    • Wypasek E, Potaczek DP, Alhenc-Gelas M, Undas A: Novel missense mutation C106R in the PROC gene associated with type I protein C deficiency in a young Polish man with high-risk pulmonary embolism. Pol Arch Med Wewn 2014, 124, 75-76.
    • (2014) Pol Arch Med Wewn , vol.124 , pp. 75-76
    • Wypasek, E.1    Potaczek, D.P.2    Alhenc-Gelas, M.3    Undas, A.4
  • 27
    • 84867435935 scopus 로고    scopus 로고
    • Dabigatran etexilate (Pradaxa®) for preventing warfarin-induced skin necrosis in a patient with severe protein C deficiency
    • Hermans C, Eeckhoudt S, Lambert C: Dabigatran etexilate (Pradaxa®) for preventing warfarin-induced skin necrosis in a patient with severe protein C deficiency. Thromb Haemost 2012, 107, 1189-1191.
    • (2012) Thromb Haemost , vol.107 , pp. 1189-1191
    • Hermans, C.1    Eeckhoudt, S.2    Lambert, C.3
  • 29
    • 84881311277 scopus 로고    scopus 로고
    • First report of a large PROS1 deletion from exon 1 through 12 detected in Polish patients with deep-vein thrombosis
    • Wypasek E, Alhenc-Gelas M, Undas A: First report of a large PROS1 deletion from exon 1 through 12 detected in Polish patients with deep-vein thrombosis. Thromb Res 2013, 132, 143-144.
    • (2013) Thromb Res , vol.132 , pp. 143-144
    • Wypasek, E.1    Alhenc-Gelas, M.2    Undas, A.3
  • 30
    • 84893652241 scopus 로고    scopus 로고
    • Heerlen polymorphism associated with type III protein S deficiency and factor v Leiden mutation in a Polish patient with deep vein thrombosis
    • Wypasek E, Potaczek DP, Alhenc-Gelas M, Undas A: Heerlen polymorphism associated with type III protein S deficiency and factor V Leiden mutation in a Polish patient with deep vein thrombosis. Blood Coagul Fibrinolysis 2014, 25, 84-85.
    • (2014) Blood Coagul Fibrinolysis , vol.25 , pp. 84-85
    • Wypasek, E.1    Potaczek, D.P.2    Alhenc-Gelas, M.3    Undas, A.4
  • 31
    • 84889887848 scopus 로고    scopus 로고
    • Protein S deficiency and Heerlen polymorphism in a Polish patient with acute myocardial infarction and previous venous thromboembolism
    • Wypasek E, Potaczek DP, Płonka J, Alhenc-Gelas M, Undas A: Protein S deficiency and Heerlen polymorphism in a Polish patient with acute myocardial infarction and previous venous thromboembolism. Thromb Res 2013, 132, 776-777.
    • (2013) Thromb Res , vol.132 , pp. 776-777
    • Wypasek, E.1    Potaczek, D.P.2    Płonka, J.3    Alhenc-Gelas, M.4    Undas, A.5
  • 33
    • 84908671635 scopus 로고    scopus 로고
    • New oral anticoagulants in thrombotic antiphospholipid syndrome
    • Chighizola CB, Moia M, Meroni PL: New oral anticoagulants in thrombotic antiphospholipid syndrome. Lupus 2014, 12, 1279-1282.
    • (2014) Lupus , vol.12 , pp. 1279-1282
    • Chighizola, C.B.1    Moia, M.2    Meroni, P.L.3
  • 34
    • 84904464844 scopus 로고    scopus 로고
    • Rivaroxaban for the long-term treatment of spontaneous ovarian vein thrombosis caused by Factor v Leiden homozygosity
    • Cook RM, Rondina MT, Horton DJ: Rivaroxaban for the long-term treatment of spontaneous ovarian vein thrombosis caused by Factor V Leiden homozygosity. Ann Pharmacother 2014, 48, 1055-1060.
    • (2014) Ann Pharmacother , vol.48 , pp. 1055-1060
    • Cook, R.M.1    Rondina, M.T.2    Horton, D.J.3
  • 38
    • 84958236838 scopus 로고    scopus 로고
    • Four good reasons to appreciate triple positivity
    • Pengo V: Four good reasons to appreciate triple positivity. Pol Arch Med Wewn 2016, 126, 7-8.
    • (2016) Pol Arch Med Wewn , vol.126 , pp. 7-8
    • Pengo, V.1
  • 39
    • 84901426902 scopus 로고    scopus 로고
    • Comment on "venous thrombosis: Who should be screened for thrombophilia in 2014?"
    • Zawilska K, Musiał J: Comment on "venous thrombosis: Who should be screened for thrombophilia in 2014?" Pol Arch Med Wewn 2014, 124, 215-216.
    • (2014) Pol Arch Med Wewn , vol.124 , pp. 215-216
    • Zawilska, K.1    Musiał, J.2
  • 40
    • 84928625226 scopus 로고    scopus 로고
    • The use of rivaroxaban in patients with antipospholipid syndrome: A series of 12 cases
    • Son M, Wypasek E, Celinska-Lowenhoff M, Undas A: The use of rivaroxaban in patients with antipospholipid syndrome: A series of 12 cases. Thromb Res 2015, 135, 1035-1036.
    • (2015) Thromb Res , vol.135 , pp. 1035-1036
    • Son, M.1    Wypasek, E.2    Celinska-Lowenhoff, M.3    Undas, A.4
  • 42
    • 84960434570 scopus 로고    scopus 로고
    • Thrombotic events in patients with antiphospholipid syndrome treated with rivaroxaban: A series of eight cases
    • Signorelli F, Nogueira F, Domingues V, Mariz HA, Levy RA: Thrombotic events in patients with antiphospholipid syndrome treated with rivaroxaban: A series of eight cases. Clin Rheumatol 2015, 35, 801-805.
    • (2015) Clin Rheumatol , vol.35 , pp. 801-805
    • Signorelli, F.1    Nogueira, F.2    Domingues, V.3    Mariz, H.A.4    Levy, R.A.5
  • 43
    • 84929471149 scopus 로고    scopus 로고
    • Rivaroxaban use in patients with antiphospholipid syndrome and previous venous thromboembolism
    • Sciascia S, Breen K, Hunt BJ: Rivaroxaban use in patients with antiphospholipid syndrome and previous venous thromboembolism. Blood Coagul Fibrinolysis. 2015, 26, 476-477.
    • (2015) Blood Coagul Fibrinolysis. , vol.26 , pp. 476-477
    • Sciascia, S.1    Breen, K.2    Hunt, B.J.3
  • 48
    • 84886736407 scopus 로고    scopus 로고
    • Main considerable factors for correct laboratory test interpretation under DOA treatment
    • Mani H, Lindhoff-Last E: Main considerable factors for correct laboratory test interpretation under DOA treatment. Thromb J 2013, 1, 11, 22.
    • (2013) Thromb J , vol.1 , Issue.11 , pp. 22
    • Mani, H.1    Lindhoff-Last, E.2
  • 49
    • 84907689006 scopus 로고    scopus 로고
    • Monitoring of anticoagulant effects of dabigatran in everyday practice: First experience in 32 Polish patients
    • Czubek U, Goralczyk T, Zalewski J, Undas A: Monitoring of anticoagulant effects of dabigatran in everyday practice: First experience in 32 Polish patients. Pol Arch Med Wewn 2014, 124, 487-489.
    • (2014) Pol Arch Med Wewn , vol.124 , pp. 487-489
    • Czubek, U.1    Goralczyk, T.2    Zalewski, J.3    Undas, A.4
  • 50
    • 84916892355 scopus 로고    scopus 로고
    • Urgent monitoring of dabigatran plasma levels: Sometimes less is more
    • Lippi G, Favaloro EJ: Urgent monitoring of dabigatran plasma levels: Sometimes less is more. Pol Arch Med Wewn 2014, 124, 639-640.
    • (2014) Pol Arch Med Wewn , vol.124 , pp. 639-640
    • Lippi, G.1    Favaloro, E.J.2
  • 51
    • 84916933343 scopus 로고    scopus 로고
    • Urgent monitoring of dabigatran plasma levels: Sometimes less is more
    • Zalewski J, Undas A: Urgent monitoring of dabigatran plasma levels: Sometimes less is more. Authors' reply. Pol Arch Med Wewn 2014, 124, 640-641.
    • (2014) Authors' Reply. Pol Arch Med Wewn , vol.124 , pp. 640-641
    • Zalewski, J.1    Undas, A.2
  • 52
    • 84988359557 scopus 로고    scopus 로고
    • Comparison of the effect of the anti-Xa direct oral anticoagulants apixaban, edoxaban, and rivaroxaban on coagulation assays
    • Gosselin R, Grant RP, Adcock DM: Comparison of the effect of the anti-Xa direct oral anticoagulants apixaban, edoxaban, and rivaroxaban on coagulation assays. Int J Lab Hematol 2016, 38, 505-513. DOI: 10.1111/ijlh.12528.
    • (2016) Int J Lab Hematol , vol.38 , pp. 505-513
    • Gosselin, R.1    Grant, R.P.2    Adcock, D.M.3
  • 53
    • 84964695907 scopus 로고    scopus 로고
    • Effects of rivaroxaban therapy on ROTEM coagulation parameters in patients with venous thromboembolism
    • Chojnowski K, Gorski T, Robak M, Treliński J: Effects of rivaroxaban therapy on ROTEM coagulation parameters in patients with venous thromboembolism. Adv Clin Exp Med 2015, 24, 995-1000.
    • (2015) Adv Clin Exp Med , vol.24 , pp. 995-1000
    • Chojnowski, K.1    Gorski, T.2    Robak, M.3    Treliński, J.4
  • 56
    • 84920262449 scopus 로고    scopus 로고
    • Comparison of the effects of apixaban and rivaroxaban on prothrombin and activated partial thromboplastin times using various reagents
    • Dale BJ, Ginsberg JS, Johnston M, Hirsh J, Weitz JI, Eikelboom JW: Comparison of the effects of apixaban and rivaroxaban on prothrombin and activated partial thromboplastin times using various reagents. J Thromb Haemost 2014, 12, 1810-1815.
    • (2014) J Thromb Haemost , vol.12 , pp. 1810-1815
    • Dale, B.J.1    Ginsberg, J.S.2    Johnston, M.3    Hirsh, J.4    Weitz, J.I.5    Eikelboom, J.W.6
  • 57
    • 84881221868 scopus 로고    scopus 로고
    • Dabigatran: Is there a role for coagulation assays in guiding therapy?
    • Brunetti L, Bandali F: Dabigatran: Is there a role for coagulation assays in guiding therapy? Ann Pharmacother 2013, 47, 828-840.
    • (2013) Ann Pharmacother , vol.47 , pp. 828-840
    • Brunetti, L.1    Bandali, F.2
  • 58
    • 84931570159 scopus 로고    scopus 로고
    • From laboratory to clinical practice: Dabigatran effects on thrombin generation and coagulation in patient samples
    • Helin TA, Lemponen M, Hjemdahl P, Ronquist-Nii Y, Lassila R, Joutsi-Korhonen L: From laboratory to clinical practice: Dabigatran effects on thrombin generation and coagulation in patient samples. Thromb Res 2015, 136, 154-160.
    • (2015) Thromb Res , vol.136 , pp. 154-160
    • Helin, T.A.1    Lemponen, M.2    Hjemdahl, P.3    Ronquist-Nii, Y.4    Lassila, R.5    Joutsi-Korhonen, L.6
  • 59
    • 84955733026 scopus 로고    scopus 로고
    • Laboratory measurement of the direct oral anticoagulants
    • Dale BJ, Chan NC, Eikelboom JW: Laboratory measurement of the direct oral anticoagulants. Br J Haematol 2016, 172, 315-336.
    • (2016) Br J Haematol , Issue.172 , pp. 315-336
    • Dale, B.J.1    Chan, N.C.2    Eikelboom, J.W.3
  • 60
    • 84872258441 scopus 로고    scopus 로고
    • Dabigatran effects on the international normalized ratio, activated partial thromboplastin time, thrombin time, and fibrinogen: A multicenter, in vitro study
    • Dager WE, Gosselin RC, Kitchen S, Dwyre D: Dabigatran effects on the international normalized ratio, activated partial thromboplastin time, thrombin time, and fibrinogen: A multicenter, in vitro study. Ann Pharmacother 2012, 46, 1627-1636.
    • (2012) Ann Pharmacother , vol.46 , pp. 1627-1636
    • Dager, W.E.1    Gosselin, R.C.2    Kitchen, S.3    Dwyre, D.4
  • 62
    • 84922394366 scopus 로고    scopus 로고
    • Laboratory measurement of the anticoagulant activity of the non-Vitamin K oral anticoagulants
    • Cuker A, Siegal DM, Crowther MA, Garcia DA: Laboratory measurement of the anticoagulant activity of the non-vitamin K oral anticoagulants. J Am Coll Cardiol 2014 16, 64, 1128-1139.
    • (2014) J Am Coll Cardiol , vol.16 , Issue.64 , pp. 1128-1139
    • Cuker, A.1    Siegal, D.M.2    Crowther, M.A.3    Garcia, D.A.4
  • 63
    • 84876459325 scopus 로고    scopus 로고
    • Novel anticoagulants and laboratory testing
    • Eby C: Novel anticoagulants and laboratory testing. Int J Lab Hematol 2013, 35, 262-268.
    • (2013) Int J Lab Hematol , vol.35 , pp. 262-268
    • Eby, C.1
  • 64
    • 84957585824 scopus 로고    scopus 로고
    • Edoxaban: Impact on routine and specific coagulation assays A practical laboratory guide
    • Douxfils J, Chatelain B, Chatelain C, Dogne JM, Mullier F: Edoxaban: Impact on routine and specific coagulation assays. A practical laboratory guide. Thromb Haemost 2016, 115, 368-381.
    • (2016) Thromb Haemost , vol.115 , pp. 368-381
    • Douxfils, J.1    Chatelain, B.2    Chatelain, C.3    Dogne, J.M.4    Mullier, F.5
  • 65
    • 84907597644 scopus 로고    scopus 로고
    • BCSH committee: Measurement of non-coumarin anticoagulants and their effects on tests of haemostasis: Guidance from the British Committee for Standards in Haematology
    • Kitchen S, Gray E, Mackie I, Baglin T, Makris M; BCSH committee: Measurement of non-coumarin anticoagulants and their effects on tests of haemostasis: Guidance from the British Committee for Standards in Haematology. Br J Haematol 2014, 166, 830-841.
    • (2014) Br J Haematol , vol.166 , pp. 830-841
    • Kitchen, S.1    Gray, E.2    Mackie, I.3    Baglin, T.4    Makris, M.5
  • 67
    • 84975764094 scopus 로고    scopus 로고
    • The laboratory's 2015 perspective on direct oral anticoagulant testing
    • Gosselin RC, Adcock DM: The laboratory's 2015 perspective on direct oral anticoagulant testing. J Thromb Haemost 2016, 14, 886-893.
    • (2016) J Thromb Haemost , vol.14 , pp. 886-893
    • Gosselin, R.C.1    Adcock, D.M.2
  • 69
    • 84928938571 scopus 로고    scopus 로고
    • False-positive lupus anticoagulant in patients receiving rivaroxaban: 24 h since the last dose are needed to exclude antiphospholipid syndrome
    • Goralczyk T, Iwaniec T, Wypasek E, Undas A: False-positive lupus anticoagulant in patients receiving rivaroxaban: 24 h since the last dose are needed to exclude antiphospholipid syndrome. Blood Coagul Fibrinolysis 2015, 26, 473-475.
    • (2015) Blood Coagul Fibrinolysis , Issue.26 , pp. 473-475
    • Goralczyk, T.1    Iwaniec, T.2    Wypasek, E.3    Undas, A.4
  • 70
    • 85019341121 scopus 로고    scopus 로고
    • Activated protein C resistance in patients following venous thromboembolism receiving rivaroxaban versus Vitamin K antagonists: Assessment using Russell viper venom time based assay
    • [in press]
    • Goralczyk T, Wojtowicz K, Undas A: Activated protein C resistance in patients following venous thromboembolism receiving rivaroxaban versus vitamin K antagonists: Assessment using Russell viper venom time based assay. Blood Coagul Fibrinolysis 2016 [in press].
    • (2016) Blood Coagul Fibrinolysis
    • Goralczyk, T.1    Wojtowicz, K.2    Undas, A.3
  • 71
    • 84898678739 scopus 로고    scopus 로고
    • Interpretation of coagulation test results under direct oral anticoagulants
    • Mani H: Interpretation of coagulation test results under direct oral anticoagulants. Int J Lab Hematol 2014, 36, 261-268.
    • (2014) Int J Lab Hematol , vol.36 , pp. 261-268
    • Mani, H.1
  • 72
    • 79851482951 scopus 로고    scopus 로고
    • Expert group on coagulation of the external quality assurance in laboratory medicine in Sweden Effects of the oral, direct thrombin inhibitor dabigatran on five common coagulation assays
    • Lindahl TL, Baghaei F, Blixter IF, Gustafsson KM, Stigendal L, Sten-Linder M, Strandberg K, Hillarp A: Expert group on coagulation of the external quality assurance in laboratory medicine in Sweden. Effects of the oral, direct thrombin inhibitor dabigatran on five common coagulation assays. Thromb Haemost 2011, 105, 371-378.
    • (2011) Thromb Haemost , vol.105 , pp. 371-378
    • Lindahl, T.L.1    Baghaei, F.2    Blixter, I.F.3    Gustafsson, K.M.4    Stigendal, L.5    Sten-Linder, M.6    Strandberg, K.7    Hillarp, A.8
  • 73
    • 84859992064 scopus 로고    scopus 로고
    • Advances in laboratory testing for thrombophilia
    • Johnson NV, Khor B, Van Cott EM: Advances in laboratory testing for thrombophilia. Am J Hematol 2012, 87, 108-112.
    • (2012) Am J Hematol , vol.87 , pp. 108-112
    • Johnson, N.V.1    Khor, B.2    Van Cott, E.M.3
  • 74
    • 84977600784 scopus 로고    scopus 로고
    • Protein S testing in patients with protein S deficiency, factor v Leiden, and rivaroxaban by North American specialized coagulation laboratories
    • Smock KJ, Plumhoff EA, Meijer P, Hsu P, Zantek ND, Heikal NM, Van Cott EM: Protein S testing in patients with protein S deficiency, factor V Leiden, and rivaroxaban by North American specialized coagulation laboratories. Thromb Haemost 2016, 116, 50-57.
    • (2016) Thromb Haemost , vol.116 , pp. 50-57
    • Smock, K.J.1    Plumhoff, E.A.2    Meijer, P.3    Hsu, P.4    Zantek, N.D.5    Heikal, N.M.6    Van Cott, E.M.7
  • 76
    • 84876192857 scopus 로고    scopus 로고
    • Measuring Oral Direct Inhibitors (ODIs) of thrombin and factor Xa: A recommendation from the Subcommittee on Control of Anticoagulation of the Scientific and Standardisation Committee of the International Society on Thrombosis and Haemostasis
    • Baglin T, Hillarp A, Tripodi A, Elalamy I, Buller H, Ageno W: Measuring Oral Direct Inhibitors (ODIs) of thrombin and factor Xa: A recommendation from the Subcommittee on Control of Anticoagulation of the Scientific and Standardisation Committee of the International Society on Thrombosis and Haemostasis. J Thromb Haemost 2013, 11, 756-760.
    • (2013) J Thromb Haemost , vol.11 , pp. 756-760
    • Baglin, T.1    Hillarp, A.2    Tripodi, A.3    Elalamy, I.4    Buller, H.5    Ageno, W.6
  • 78
    • 84933500385 scopus 로고    scopus 로고
    • New oral anticoagulants: Their advantages and disadvantages compared with Vitamin K antagonists in the prevention and treatment of patients with thromboembolic events
    • Mekaj YH, Mekaj AY, Duci SB, Miftari EI: New oral anticoagulants: their advantages and disadvantages compared with vitamin K antagonists in the prevention and treatment of patients with thromboembolic events. Ther Clin Risk Manag 2015, 11, 967-977.
    • (2015) Ther Clin Risk Manag , vol.11 , pp. 967-977
    • Mekaj, Y.H.1    Mekaj, A.Y.2    Duci, S.B.3    Miftari, E.I.4


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.